ArsudaClinical Research

Site network for
your next clinical trial in Armenia

Established clinical expertise, a coordinated approach to research operations, and a commitment to quality-driven site development. Connect with Arsuda to explore protocol feasibility in Armenia.

Request site feasibility

Why Armenia. Why Arsuda.

Established clinical relationships

Collaborating physicians are active specialists with established clinical practices and patient populations. Patient eligibility and recruitment potential are evaluated against each protocol.

Clinical leadership and expertise

The network is built around experienced physicians, including specialists with senior clinical responsibilities. Individual investigator qualifications can be discussed during feasibility with appropriate authorization.

A differentiated research opportunity

Arsuda aims to connect existing clinical expertise in Armenia with the processes, documentation and coordinated operations expected by international research partners.

Quality-led operating model

Our approach emphasizes GCP-aligned quality systems, electronic essential-document workflows, staff development and protocol-specific site qualification.

Capabilities aligned to your protocol

Phase I–IV interventional drug and device studies in patient populations, and non-interventional studies, led by specialists in oncology, cardiovascular disease and other major therapeutic areas.
Explore therapeutic areas →
Site-assessed and ISO 9001-certified facilities, with the clinical space, imaging, laboratory and sample-handling capability your protocol requires.
A quality-driven approach to site processes, electronic documentation, research team training and sponsor-facing collaboration.
Experienced site staff work in line with ICH-GCP, including ICH E6(R3), focusing on the factors critical to quality in each protocol, with oversight at every step to protect participant safety and deliver data you can rely on. Quality documentation is available on request.
Our quality and compliance expertise →

From final protocol to site activation

Final protocol to site activation

14–21 weeks

Medicinal product study, typical range

  1. Submission dossier

    Prepared from your core study documents.

    4–6 weeks

  2. Ethics committee, then Ministry of Health

    Sequential review.

    8–13 weeks

  3. Import license

    Issued once the study is approved.

    2 weeks

  4. Site activation

  1. Submission dossier

    Prepared from your core study documents

    4–6 weeks

  2. Ethics committee, then Ministry of Health

    Sequential review

    8–13 weeks

  3. Site contracts and budgets

    Negotiated alongside the EC and MoH review

    2–4 weeks

  4. Import license

    Issued once the study is approved

    2 weeks
Typical fastestUp to typical slowestWeeks from start

Looking for sites for your next trial?

Share a protocol synopsis or feasibility questionnaire. We will assess investigator fit, clinical capabilities and site-specific requirements before proposing a path forward.

Request site feasibility info@arsuda.com

Facilities and diagnostics

AreaWhat we provideWhat it means for your study
AccreditationSite-assessed and ISO 9001-certified facilitiesPatient safety and quality management benchmarked against international standards.
Clinical spaceExamination rooms, infusion capability and inpatient beds, configured to each studyOutpatient visits, infusion protocols and overnight observation in one setting.
Emergency careAccess to emergency careParticipant safety for infusions and early-phase dosing.
ImagingCT, MRI, PET-CT and ultrasoundImaging endpoints and safety assessments, including tumor response assessments.
Cardiac monitoring12-lead ECGCardiac safety monitoring, including QTc assessment.
Laboratory servicesClinical and specialty laboratories, including pathology and geneticsLocal safety labs, biopsy review and biomarker work.
Sample handlingSample processing with storage at −20 °C and −80 °CSample integrity maintained until shipment to central laboratories.

Data and systems

AreaWhat we provideWhat it means for your study
Electronic site file (eISF)Regulatory and study documents managed and signed electronicallyAn inspection-ready file, with remote access for monitors.
Study tracking (CTMS)Enrollment, visits and milestones tracked in one systemClear, current study status for sponsors and CROs.
eSourceData captured electronically at the point of careFewer transcription errors and faster source data verification.
eConsentElectronic informed consentVersion control and a complete audit trail of the consent process.
Regulatory complianceFDA 21 CFR Part 11, EU Annex 11, HIPAA and GDPRAudit trails, electronic signatures and data protection that meet US and EU expectations.
Data integritySource data recorded to ALCOA++ principlesAttributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available and traceable data.
Sponsor systemsExperience with EDC, eCOA/ePRO and IRT platformsFaster onboarding to your systems and fewer data queries.